Description
Product overview
Tirzepatide is a synthetic 39 amino-acid peptide developed by Eli Lilly, marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Supplied as 10mg lyophilised per vial. The first dual GLP-1/GIP receptor agonist in clinical use.
Receptor profile
Tirzepatide co-activates two incretin receptors:
- GLP-1 receptor — appetite suppression, gastric slowing, glucose-dependent insulin release
- GIP receptor — insulin sensitisation, adipose lipid handling, possible nausea attenuation
The receptor balance is slightly GIP-favoured at physiological concentrations. The C20 fatty diacid sidechain enables albumin binding for ~5-day plasma half-life.
Trial data summary
SURMOUNT-1 (Jastreboff et al., NEJM 2022): mean body weight reduction of 22.5% at 72 weeks with 15mg weekly dosing — the largest weight-loss endpoint among dual-agonist class molecules. SURPASS-2 head-to-head trial showed tirzepatide outperforming semaglutide on both glycaemic and weight endpoints across all three dose arms.
See our Mounjaro mechanism article, tirzepatide vs semaglutide head-to-head, and brand comparison.
Research applications
- Dual incretin receptor pharmacology
- GIP biology research
- Metabolic and weight regulation models
- Combined glycaemic + weight endpoint research
Reconstitution and storage
Reconstitute with bacteriostatic water at 1–2 mL for working concentrations of 5–10 mg/mL. The 39 amino-acid sequence is more sensitive to repeated freeze-thaw than shorter peptides — single freeze-thaw acceptable, multiple cycles degrade integrity. Refrigerate (2–8°C), stable approximately 4 weeks after reconstitution.
Quality and analytics
HPLC purity ≥98%. Batch-specific Certificate of Analysis with mass spectrometry confirmation available on request.
For laboratory research use only. Not for human or veterinary use.
